Who
James E. Dentzer
Director
Company insider
Files Form 4 as: Director, Imunon; President & CEO, Curis; Chief Financial Officer, Dicerna Pharmaceuticals; Chief Financial Officer, Amicus Therapeutics.
In numbers
- Trades disclosed
- 79
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $92K
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 2 Oct 2007
- Last trade
- 31 Jul 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Jul 2026filed 4 Aug 2026 | IMNN ImunonBiotechnology | SEC FORM 4 Code A | $11K6,934 at $1.59 | filing |
| 31 Jul 2026filed 4 Aug 2026 | IMNN ImunonBiotechnology | SEC FORM 4 Code A | $11K6,934 at $1.59 | filing |
| 7 Jul 2026filed 9 Jul 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | $582K110,090 at $5.29 | filing |
| 7 Jul 2026filed 9 Jul 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | $582K110,090 at $5.29 | filing |
| 22 May 2026filed 27 May 2026 | IMNN ImunonBiotechnology | SEC FORM 4 Code A | $25K11,148 at $2.20 | filing |
| 22 May 2026filed 27 May 2026 | IMNN ImunonBiotechnology | SEC FORM 4 Code A | $25K11,148 at $2.20 | filing |
| 20 Mar 2026filed 23 Mar 2026 | CRIS CurisBiotechnology | SEC FORM 4 Code C | —133,333 | filing |
| 20 Mar 2026filed 23 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code C | —100 | filing |
| 20 Mar 2026filed 23 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code C | —100 | filing |
| 20 Mar 2026filed 23 Mar 2026 | CRIS CurisBiotechnology | SEC FORM 4 Code C | —133,333 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —100 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —133,333 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —133,333 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —100 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —133,333 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —133,333 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —133,333 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —133,333 | filing |
| 2 Jan 2026filed 6 Jan 2026 | IMNN Imunonoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,405 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | IMNN Imunonoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,405 at $0.00 | filing |
News
Reviewing Soligenix (NASDAQ:SNGX) and Curis (NASDAQ:CRIS)CRIS · themarketsdaily.com · 17 Oct 2026
0 headlines in the last 90 days name James E. Dentzer; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.